IGF2BP3 and neoplasm: JQ1 123 and I-BET151 27, belonging to the bromodomain and extraterminal domain class of inhibitors, have been validated to downregulate IGF2BP3 expression and impair tumor growth in Ewing sarcoma and mixed-lineage leukemia-rearranged B-acute lymphoblastic leukemia.